Aevi Genomic Medicine (Aevi Genomic Medicine) Interest Expense : $0.00 Mil (TTM As of Sep. 2019)

View and export this data going back to 2007. Start your Free Trial

What is Aevi Genomic Medicine Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aevi Genomic Medicine's interest expense for the three months ended in Sep. 2019 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aevi Genomic Medicine's Operating Income for the three months ended in Sep. 2019 was $ -4.04 Mil. Aevi Genomic Medicine's Interest Expense for the three months ended in Sep. 2019 was $ 0.00 Mil. Aevi Genomic Medicine has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Aevi Genomic Medicine Interest Expense Historical Data

The historical data trend for Aevi Genomic Medicine's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aevi Genomic Medicine Interest Expense Chart

Aevi Genomic Medicine Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Interest Expense

Get a 7-Day Free Trial

-0.02

Aevi Genomic Medicine Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Aevi Genomic Medicine Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aevi Genomic Medicine (NAS:GNMX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aevi Genomic Medicine's Interest Expense for the three months ended in Sep. 2019 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2019 was $-4.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2019 was $0.00 Mil.

Aevi Genomic Medicine's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as

Aevi Genomic Medicine had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (NAS:GNMX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087

Website

http://www.aevigenomics.com

Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.

Executives

Michael F Cola	director, officer: Chief Executive Officer	435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Garry Arthur Neil	officer: Chief Scientific Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Eugene A Bauer	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Alastair J Clemow	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Grano Joseph J Jr	director	C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Plc Astrazeneca	10 percent owner	1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0 CB2 0AA
Brian Piper	officer: CFO & Corporate Secretary	C/O MEDGENICS, INC., 435 DEVON PARK DRIVE, BLDG. 700, WAYNE PA 19087
Wilbur H Gantz	director	C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Scott Applebaum	officer: Chief Legal Officer	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
John Harold Leaman	officer: Chief Financial Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Clarence L Dellio	officer: Chief Operating Officer	435 DEVON PARK DRIVE BLDG 700, C/O MEDGENICS, INC., WAYNE PA 19087